Search results for "Particle"

showing 10 items of 15225 documents

"Table 29" of "K$^{*}(892)^{0}$ and $\phi(1020)$ meson production at high transverse momentum in pp and Pb-Pb collisions at $\sqrt{s_\mathrm{NN}}$ = …

2017

p/$\phi$ ratio as a function of $p_{\rm T}$ for inelastic (INEL) pp collisions at $\sqrt{s}=2.76~{\rm TeV}$.

2760.0pT differential particle ratioHigh Energy Physics::ExperimentP P --> Phi XNuclear Experiment
researchProduct

"Table 19" of "K$^{*}(892)^{0}$ and $\phi(1020)$ meson production at high transverse momentum in pp and Pb-Pb collisions at $\sqrt{s_\mathrm{NN}}$ = …

2017

$\phi$/K ratio as a function of $p_{\rm T}$ for inelastic (INEL) pp collisions at $\sqrt{s}=2.76~{\rm TeV}$.

2760.0pT differential particle ratioHigh Energy Physics::ExperimentP P --> Phi XNuclear Experiment
researchProduct

"Table 23" of "K$^{*}(892)^{0}$ and $\phi(1020)$ meson production at high transverse momentum in pp and Pb-Pb collisions at $\sqrt{s_\mathrm{NN}}$ = …

2017

$\phi$/$\pi$ ratio as a function of $p_{\rm T}$ for inelastic (INEL) pp collisions at $\sqrt{s}=2.76~{\rm TeV}$.

2760.0pT differential particle ratioHigh Energy Physics::ExperimentP P --> Phi XNuclear Experiment
researchProduct

"Table 18" of "K$^{*}(892)^{0}$ and $\phi(1020)$ meson production at high transverse momentum in pp and Pb-Pb collisions at $\sqrt{s_\mathrm{NN}}$ = …

2017

$\phi$/K ratio as a function of $p_{\rm T}$ for 0-5$\%$ centrality in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76~{\rm TeV}$.

2760.0pT differential particle ratioPB PB --> Phi X
researchProduct

"Table 27" of "K$^{*}(892)^{0}$ and $\phi(1020)$ meson production at high transverse momentum in pp and Pb-Pb collisions at $\sqrt{s_\mathrm{NN}}$ = …

2017

p/$\phi$ ratio as a function of $p_{\rm T}$ for 0-5$\%$ centrality in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76~{\rm TeV}$.

2760.0pT differential particle ratioPB PB --> Phi X
researchProduct

"Table 22" of "K$^{*}(892)^{0}$ and $\phi(1020)$ meson production at high transverse momentum in pp and Pb-Pb collisions at $\sqrt{s_\mathrm{NN}}$ = …

2017

$\phi$/$\pi$ ratio as a function of $p_{\rm T}$ for 0-5$\%$ centrality in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76~{\rm TeV}$

2760.0pT differential particle ratioPB PB --> Phi X
researchProduct

"Table 28" of "K$^{*}(892)^{0}$ and $\phi(1020)$ meson production at high transverse momentum in pp and Pb-Pb collisions at $\sqrt{s_\mathrm{NN}}$ = …

2017

p/$\phi$ ratio as a function of $p_{\rm T}$ for 60-80$\%$ centrality in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76~{\rm TeV}$.

2760.0pT differential particle ratioPB PB --> Phi X
researchProduct

PHEA-PLA biocompatible nanoparticles by technique of solvent evaporation from multiple emulsions

2015

Nanocarriers of amphiphilic polymeric materials represent versatile delivery systems for poorly water soluble drugs. In this work the technique of solvent evaporation from multiple emulsions was applied to produce nanovectors based on new amphiphilic copolymer, the α,β-poly(N-2-hydroxyethyl)-DL-aspartamide-polylactic acid (PHEA-PLA), purposely synthesized to be used in the controlled release of active molecules poorly soluble in water. To this aim an amphiphilic derivative of PHEA, a hydrophilic polymer, was synthesized by derivatization of the polymeric backbone with hydrophobic grafts of polylactic acid (PLA). The achieved copolymer was thus used to produce nanoparticles loaded with α toc…

3003Biocompatible polymerPolymersChemistry PharmaceuticalDrug CompoundingPolyestersalpha-TocopherolPharmaceutical Sciencechemistry.chemical_compoundDrug Delivery SystemsNanoparticlePolylactic acidAmphiphileOrganic chemistryLactic AcidSolubilityDrug CarriersUltrasonic energyPHEA-PLAEmulsionAmphiphilic polymerControlled releaseSolventDrug LiberationSolubilitychemistryChemical engineeringDelayed-Action PreparationsDrug deliveryDrug deliverySolventsNanoparticlesEmulsionsNanocarriersPeptidesDrug carrierHydrophobic and Hydrophilic Interactions
researchProduct

Spray dried hyaluronic acid microparticles for adhesion controlled aggregation and potential stimulation of stem cells

2017

Spray-dried microparticles of a derivative of hyaluronic acid (HA) have been engineered to obtain a controlled aggregation with Human Mesenchymal Stem Cells (hMSCs) into 3D constructs. We demonstrated the utility of chemical functionalization of a native constituent of the extracellular matrix to improve processing performances and to control on stem cell adhesion and differentiation. Native hyaluronic acid (HA), cell adhesive peptides (RGD), transforming growth factor β3, dexamethasone are biological agents potentially suitable for chondrogenic stimulation of hMSCS. However unmodified HA suffers of drawbacks in terms of stability and versatility of processing. Functionalization strategies…

3003Hyaluronic acid0206 medical engineeringPharmaceutical Science02 engineering and technologyDexamethasoneExtracellular matrixchemistry.chemical_compoundTissue engineeringTransforming Growth Factor betaHyaluronic acidCell AdhesionHumansCell adhesionCells CulturedBottom-up approachStem cellMesenchymal Stromal CellTissue EngineeringChemistryMesenchymal stem cellMesenchymal Stem CellsCell DifferentiationAdhesion021001 nanoscience & nanotechnology020601 biomedical engineeringExtracellular MatrixBiochemistryMicroparticleSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSurface modificationChondrogenesiStem cell0210 nano-technologyChondrogenesisHuman
researchProduct

Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.

2017

Abstract In this paper, we describe the preparation of polymeric nanoparticles (NPs) loaded with sorafenib for the treatment of hepatocellular carcinoma (HCC). A synthetic brush copolymer, named PHEA-BIB-ButMA (PBB), was synthesized by Atom Trasnfer Radical Polymerization (ATRP) starting from the α-poly( N -2-hydroxyethyl)- d , l -aspartamide (PHEA) and poly butyl methacrylate (ButMA). Empty and sorafenib loaded PBB NPs were, then, produced by using a dialysis method and showed spherical morphology, colloidal size, negative ζ potential and the ability to allow a sustained sorafenib release in physiological environment. Sorafenib loaded PBB NPs were tested in vitro on HCC cells in order to e…

3003MaleHepatocellular carcinomamedicine.medical_treatmentPharmaceutical Science02 engineering and technologyATRPPharmacology01 natural sciencesDrug Delivery SystemsCopolymerChemistryATRP; Hepatocellular carcinoma; Sorafenib; Tumor targeting; α-Poly(N-2-hydroxyethyl)-DL-aspartamide; 3003Liver NeoplasmsSorafenib021001 nanoscience & nanotechnologyDrug delivery0210 nano-technologymedicine.drugSorafenibNiacinamideCarcinoma HepatocellularCell SurvivalRadical polymerizationIntraperitoneal injectionL-aspartamideMice NudeAntineoplastic AgentsEnhanced permeability and retention effect010402 general chemistryPolymethacrylic AcidsIn vivoCell Line TumormedicineAnimalsHumansneoplasmsProtein Kinase InhibitorsPhenylurea Compoundstechnology industry and agriculturedigestive system diseasesIn vitro0104 chemical sciencesDrug LiberationTumor targetingDelayed-Action PreparationsBiophysicsα-Poly(N-2-hydroxyethyl)-DNanoparticlesα-Poly(N-2-hydroxyethyl)-DL-aspartamidePeptidesJournal of controlled release : official journal of the Controlled Release Society
researchProduct